Menu
Recruiting NCT05678413

Role of Paclitaxel in Stricture Urethra

No phase Interventional Stricture Urethra

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: DVIU with paclitaxel injection, DVIU.
Who it may be relevant to
Registry conditions: Stricture Urethra. Basic parameters: from 18 years · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Role of Paclitaxel in Prevention of Stricture Recurrence After Direct Visual Internal Urethrotomy (DVIU); Prospective Clinical Trial

Overview

Stricture urethra is a common disease and has various causing factors. The most common performed procedure is direct visual internal urethrotomy (DVIU), but unfortunately has a high recurrence rates. Multiple trial were performed to improve the outcomes of DVIU. Various intralesional injections were used. in this trial we will evaluate intralesional paclitaxel injection following DVIU.

Interventions

  • Procedure DVIU with paclitaxel injection
    Cystourethroscopy will be performed using a 22 Fr rigid cystoscope to allow for ureteric catheter 3F/a wire to be passed through the stricture and into the urinary bladder. DVIU will be performed by cold-knife incisions at the 12-, 3-, and 9 o'clock positions through the full thickness of the fibrosis to healthier appearing tissue. A 23 Fr Wolf (Vernon Hills, IL) injection scope and a standard injection needle was used to inject 30 mg/5mL of paclitaxel vial, 1.5 mL will be injected along the len
  • Procedure DVIU
    DVIU

Primary outcome measures

  • Success of treatment [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Anterior urethral stricture
  • Short strictures (less than 2 cm)
  • International Prostate Symptom Score less than 11 and maximum flow rate < 15 ml per second.
  • No previous treatment for stricture disease

Exclusion criteria

  • Recurrent cases
  • Prior pelvic radiation
  • Associated other pathology or unresolved confounding etiologies (e.g. bladder neck contracture, neurogenic bladder, benign prostatic hyperplasia) were excluded.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • Mohamed Fawzy Salman — Cairo

Identifiers

NCT: NCT05678413 · Intraurethral Paclitaxel

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗